Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
Safety Reporting IN Clinical Trials
ADVERSE EVENT REPORTING
What is a Data and Safety Monitoring Plan and how do I get one? Presented by Office of Human Research Protection.
UNANTICIPATED PROBLEMS INVOLVING RISKS TO SUBJECTS OR OTHERS & INCIDENTS OF NON-COMPLIANCE ( AKA PROTOCOL DEVIATIONS ) TRACY RIGHTMER, JD, CIP COMPLIANCE.
UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
Reporting Unanticipated Problems Involving Risk to Subjects or Others and Adverse Events WFUHS Policy/Procedure Effective Date 6/1/07 Wendy Murray Monitoring.
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
Update: 21 CFR PART 312 FDA Safety Reporting Requirements for INDs
Capturing and Reporting Adverse Events in Clinical Research
Director, Investigator Support & Integration Services, OCTRI
Fulfilling the Promise of Medicine Together New FDA Safety Reporting Requirements 2010 John McLane, Ph.D. COO & Vice President Clinical and Regulatory.
IRB-Investigator/ Research Coordinator Mtg. “CUMC’s New Progressive Policy For Adverse Event Reporting” April 13, 2004 George Gasparis Andrew Wit, Ph.D.
Human Research Protection Program CHR Post-Approval Event Reporting Wednesday, April 11, 2012 Beth Shields, MA, CIP, CCRA Quality Assurance Coordinator.
Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.
Human Research Protection Program Training: Post-Approval Event Reporting March 26, 2008 Lisa Voss, MPH, CIP Assistant Director, QIU Human Research Protection.
Vanderbilt Human Research Protections Program
Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.
Defining Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
Continuing Review VA Requirements Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst Program for Research Integrity Development and Education (PRIDE)
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
Paula Peyrani, MD Division of Infectious Diseases University of Louisville Performing the Study.
THE ROLE OF DSMB’s in CLINICAL RESEARCH Data and Safety Monitoring Monitoring.
Using the short form and reporting adverse events Erin Coons, Senior IRB Specialist, COMIRB 1.
Reporting Unanticipated Problems and Adverse Events: A Change in Policy Mary A. Banks RN, BS, BSN Director, BUMC IRB Wednesday, November 14, 2007.
Unanticipated Problems Potentially Involving Risks to Subjects or Others Research Protections Office Serving UVM and FAHC Updated April 2012.
New Adverse Event Reporting Policy Effective September 1, 2007.
Office of Research Oversight ORO Reporting Adverse Events in Research to ORO Paula Squire Waterman, MS, CIP Department of Veterans Affairs Office of Research.
Investigational New Drug Application (IND)
EMORY INSTITUTIONAL REVIEW BOARD VERSION Unanticipated Problems, Protocol Deviations and Non-Compliance.
Common Audit Findings UTHSC Institutional Review Board (IRB)
Michelle Groy Johnson Quality Improvement Officer Research Integrity Office Tough Love: Understanding the Purpose and Processes of Quality Assurance.
Planned Emergency Research Exception from Informed Consent Requirements September 2007.
Adverse Event/Unanticipated Problems Policy and Procedures November 2007.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
AE/SAE/EAE Identification and Reporting AE/SAE/EAE Identification and Reporting.
Office of Research Oversight 1 VHA Handbook Research Compliance Reporting Requirements Revised May 21, 2010 (Presentation prepared for HRPP 101,
Understanding Unanticipated Problems (UPs) Elizabeth Ness, RN, MS Director, Staff Development Office of the Clinical Director Center for Cancer Research,
Inside Clinical Trials ® ALL RIGHTS RESERVED. What is a clinical trial? ALL RIGHTS RESERVED.
Investigational Devices and Humanitarian Use Devices June 2007.
Office of Research Oversight 1 Office of Research and Development Local Accountability Meeting January 2009.
Adverse Events, Unanticipated Problems, and Protocol Deviations Kathleen O’Malley RN, BSN, CCRP Manager of Education and Training Jefferson Clinical Research.
GEORGIA STATE UNIVERSITY IRB ADAPTED FROM DHHS GUIDANCE ON UNANTICIPATED PROBLEMS Unanticipated Problems.
Main Line Hospitals Institutional Review Board Unanticipated Problems Anne Marie Hobson, BSN, JD, ORA Director Theresa Greaves, ORA Manager.
Instructions for New IRB Continuing Review (Progress) Report
Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Introduction Review and proper registration of Human Gene Transfer protocols is very complex. A protocol goes through rigorous review by multiple Committees.
Dartmouth Human Research Protection Program (HRPP) Data Safety Monitoring and Reporting requirements Brown Bag Series: Noon / First Tuesday of the Month.
Susan Sonne, PharmD, BCPP Chair, MUSC IRB II
Reportable Events Emory IRB 9/11/2014.
IRB reporting updates.
FDA’s IDE Decisions and Communications
What is a Data and Safety Monitoring Plan and how do I get one?
Reportable Events & Other IRB Updates February 2017
Adverse Event Reporting: Trials and Tribulations
Remote Monitoring of Adverse Events
Pharmacovigilance in clinical trials
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Remote Monitoring of Adverse Events
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Navigating Non-Compliance
SERIOUS ADVERSE EVENTS REPORTING
Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Reporting to the CPHS: Unanticipated Problems & Serious Adverse Events
Ramy Abdelrahman, MD Division of Pediatric and Maternal Health (DPMH)
Event Reporting in Human Subjects Research
Presentation transcript:

Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?

Reason for Reporting Unanticipated Problems “to assure the protection of the rights and welfare of the human subjects”

UTHSC IRB Submission Forms 4a: Reportable local adverse events 4b: Reportable external adverse events 4c: Protocol problem or protocol deviation/violation 4d: Non-reportable local or external adverse events or problems 4e: Methodist Hospital & Le Bonheur Children’s Hospital adverse event Data Safety Monitoring Board (DSMB)/Annual Reports

Adverse Event (adverse effect, adverse experience, unanticipated problem or unanticipated adverse device effect) Any untoward or unfavorable medical occurrence in a human subject, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the subject’s participation in the research, whether or not considered related to the subject’s participation in the research.

Internal vs. External Adverse Events (AEs) Internal Adverse Events For a multi-center trial, those AEs experienced by subjects enrolled by the local investigator at the institution For a single center trial, all AEs would be considered internal External Adverse Events Those AEs experienced by subjects enrolled by investigators at other institutions engaged in the clinical trial

Serious Adverse Event (AE) Death Life-threatening (places the subject at immediate risk of death from the event as it occurred Inpatient hospitalization or prolongation of existing hospitalization Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions Congenital anomaly/birth defect Any other AE that, based upon appropriate medical judgment, may jeopardize the subject’s health and may require medical or surgical intervention to prevent one of the other outcomes listed

Unexpected Adverse Event (AE) An AE or suspected adverse reaction is considered “unexpected” if it is: Not listed in the investigator’s brochure (IB), package inserts, or product labeling, or not listed at the specificity or severity that has been observed Not consistent with the risk information described in the general investigational plan (protocol) or elsewhere in the current application (consent form)

Relationship of AE to Research What is the likelihood that the AE, incident, experience or outcome may have been caused by the procedures involved in the research: Possibly; Probably; or Clearly caused by research intervention

IRB Procedures for submitting Unanticipated Problems/AE Use the appropriate Form 4 via iMedRIS: 4a: Reportable local adverse events 4b: Reportable external adverse events 4d: Non-reportable local or external adverse events or problems 4e: Methodist Hospital & Le Bonheur Children’s Hospital adverse event

Data Safety Monitoring Board (DSMB) or Data Monitoring Committee (DMC) The FDA defines a DSMB as: “a group of individuals with pertinent experience that reviews on a regular basis accumulating data from an ongoing trial. The DSMB advised the sponsor regarding the continuing safety of current participants and those yet to be recruited, as well as the continuing validity and scientific merit of the trial.”

Purpose of a DSMB or DMC Identify unacceptably slow rates of accrual Identify high rates of ineligibility determined after randomization Identify protocol violations that suggest clarification of changes to protocol are needed Identify unexpectedly high dropout rates that threaten the trial’s ability to produce credible results Ensure the credibility of the study Ensure the validity of study results Protect the safety of trial participants

Is a DSMB necessary for my study? Is there a large study population, or are there multiple study sites? Is the trial intended to provide definitive information about effectiveness and/or safety of a medical intervention? Do prior data suggest that the intervention being studied has the potential to induce unacceptable toxicity? Does the trial evaluate mortality or another major endpoint, such that inferiority of one treatment arm has safety and effectiveness implications? Would it be ethically important for the trial to stop early if the primary question addressed has been definitively answered, even if secondary questions or complete safety information were not yet fully addressed?

IRB Procedure Use the iMedRIS Submission Form “Data Safety Monitoring Board/Annual Reports” for the following: FDA Safety Alerts FDA Public Health Advisories DSMB/DMC Reports Sponsor Interim or Annual Reports *Must be submitted with 10 working days of receipt by the investigator

Protocol Deviations/Violations A failure to follow procedures specified in the approved research protocol in the absence of a protocol waiver.

Major vs. Minor Protocol Deviations has no substantive effect on the risks or benefits for the individual research subject, and has no substantive effect on the value of the data collected, and does not result from willing or knowing misconduct on the part of an investigator or study staff. Major Protocol Deviation: has harmed or has posed a significant risk of substantive harm to the individual research subject, or has compromised the scientific integrity of the data collected for the study, or appears to result from the willing or knowing misconduct on the part of an investigator or study staff, or appears to involve some other serious or continuing noncompliance with federal, state or local research regulations.

Protocol Waiver (Eligibility Exception or Eligibility Waiver) A prospective decision by a sponsor or investigator to permit accrual of a subject who does satisfy the approved inclusion/exclusion criteria for enrollment.

IRB Procedure Submit a Form 4c: Protocol problem or protocol deviation/violation via iMedRIS All major protocol deviations must be reported with 5 working days Minor protocol deviations are not required to be submitted for IRB review Protocol waivers from a study sponsor must include supporting documentation from the sponsor

iMedRIS https://ris01.uthsc.edu

UTHSC IRB Website http://www. uthsc